πŸ›’ Your Cart

πŸš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
πŸ“ US-Based Research Peptide Supplier  |  info@truetide.com
πŸ’š Immune & Cellular CAS: 69679-67-0 βœ“ 99%+ Purity

KPV
Ξ±-MSH Tripeptide β€” Lys-Pro-Val

β˜…β˜…β˜…β˜…β˜…4.8 / 5  Β·  Anti-inflammatory tripeptide β€” gut & skin research

Select Size

$49
10mg
βœ“
99%+ purity, independently verified by HPLC & mass spectrometry
❄
Lyophilized vials β€” shipped with cold pack, stable at βˆ’20Β°C long term
πŸ“„
Certificate of Analysis included with every order
🚚
Same-day dispatch on orders before 2PM EST
πŸ”’
Discreet, unmarked packaging β€” research-grade handling
⚠️ For Research Use Only. KPV is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is KPV?

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of Ξ±-melanocyte-stimulating hormone (Ξ±-MSH). Despite being only three amino acids, KPV retains the potent anti-inflammatory activity of the full Ξ±-MSH sequence. It acts on melanocortin receptors (particularly MC1R and MC3R) and NF-ΞΊB pathways to suppress pro-inflammatory cytokine cascades, making it a key compound for IBD, skin inflammation, and systemic immune research.

CAS 69679-67-0 | MW 328.4 Da

Melanocortin Receptor

Binds MC1R and MC3R on immune cells, triggering cAMP-mediated suppression of NF-ΞΊB activity and downstream inflammatory signalling.

Cytokine Suppression

Reduces TNF-Ξ±, IL-1Ξ², IL-6, and IL-8 in lipopolysaccharide-challenged macrophage models by 60–80% in published studies.

Gut Epithelial Protection

Acts directly on intestinal epithelial cells to reduce permeability and inflammatory signalling β€” key for IBD research models.

Cell Penetrating

Small size (MW 328 Da) enables intracellular penetration and access to nuclear inflammatory targets unlike larger peptides.

IBD Anti-inflammatory Activity

Dalmasso et al. demonstrated KPV significantly reduced colitis severity in DSS-treated mice, decreasing histological damage scores and mucosal cytokine levels compared to controls.

Am J Physiol Gastrointest Liver Physiol. 2008;294(4):G1060–1067

Skin Inflammation Research

Chavan et al. showed KPV suppressed UVB-induced skin inflammation in human keratinocyte models, reducing CXCL8 and IL-6 by >70%.

J Invest Dermatol. 2010;130(4):1024–1032

Nanoparticle Delivery Research

Laroui et al. developed KPV-loaded nanoparticles that orally targeted inflamed colon tissue, demonstrating effective anti-inflammatory delivery in IBD mouse models.

Gastroenterology. 2010;138(3):843–853

Research Dosing Protocols

In vivo IBD studies use 1–10 Β΅g/day SC or oral delivery with nanoparticle formulation. In vitro macrophage/epithelial studies use 0.1–10 Β΅M concentration ranges. Cytokine panels (TNF-Ξ±, IL-1Ξ², IL-6) and histological scoring are standard endpoints. Often paired with BPC-157 in gut healing stack research.

Research Note: KPV is frequently studied via oral nanoparticle delivery for targeted gut exposure β€” a distinct delivery research application.
Full NameKPV (Lys-Pro-Val)
CAS Number69679-67-0
Molecular FormulaC₁₅H₂₉N₃Oβ‚„
Molecular Weight328.4 Da
SequenceLys-Pro-Val
OriginC-terminal fragment of Ξ±-MSH
Purityβ‰₯99% by HPLC
Storageβˆ’20Β°C, desiccated